Exalenz Bioscience has secured humanitarian device exemption status from the FDA for its BreathID device in the diagnosis of acute liver failure, shortening its process to FDA approval. The designation comes a week after the company received FDA approval for a clinical study designed to evaluate the efficacy of the device in detecting liver cancer at an early stage.

Full Story:
Globes (Israel)

Related Summaries